SPONSOR
Allist Pharmaceuticals, Inc.
Total Trials
2
Recruiting
2
Phases
Phase 3
Allist Pharmaceuticals, Inc. is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including NSCLC, Adjuvant Treatment, EGFR, NSCLC (Advanced Non-small Cell Lung Cancer).
The trial portfolio spans Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Allist Pharmaceuticals, Inc.
How many clinical trials has Allist Pharmaceuticals, Inc. sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Allist Pharmaceuticals, Inc., of which 2 are actively recruiting participants. These trials cover conditions including NSCLC, Adjuvant Treatment, EGFR. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Allist Pharmaceuticals, Inc. research focus on?
Allist Pharmaceuticals, Inc. clinical trials span NSCLC, Adjuvant Treatment, EGFR, NSCLC (Advanced Non-small Cell Lung Cancer). The research pipeline includes Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Allist Pharmaceuticals, Inc. clinical trial?
To participate in a Allist Pharmaceuticals, Inc. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Allist Pharmaceuticals, Inc. trials with current recruitment status updated daily.
Clinical Trials by Allist Pharmaceuticals, Inc.
NCT07010419 Phase 3
Recruiting
A Study to Assess the Efficacy and Safety of Firmonertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB - IIIB NSCLC With Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations, Following Complete Surgical Resection With or Without Adjuvant Chemotherapy（FIRMOST）
NSCLC
NCT06956001 Phase 3
Recruiting
Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation
EGFR
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: April 2026 · Data Methodology